FIU Research Expands Cancer Treatment Options with Functional Precision Medicine
Event summary
- Florida International University (FIU) researchers, led by Diana Azzam, are advancing functional precision medicine for cancer treatment.
- The Tyler Trent Foundation provided a philanthropic gift to accelerate Azzam's lab's research.
- Preliminary findings suggest expanded drug testing may enhance treatment effectiveness and speed.
- The approach focuses on testing existing drugs on living tumor cells, moving beyond genetic mutation analysis.
- The research aims to identify viable therapies for patients with recurrent or treatment-resistant cancers.
The big picture
The increasing prevalence of treatment-resistant cancers and the limitations of traditional genomic-based precision oncology are driving demand for alternative therapeutic approaches. FIU's functional precision medicine research represents a shift towards a more holistic assessment of drug response, potentially unlocking treatment options for patients with limited alternatives. This philanthropic investment underscores the growing recognition of the value of drug repurposing and personalized treatment strategies in oncology.
What we're watching
- Clinical Validation
- The success of this functional precision medicine approach hinges on rigorous clinical validation to confirm the early positive findings and demonstrate broader applicability across cancer types.
- Regulatory Pathway
- The accelerated translation of repurposed drugs into clinical use will depend on navigating regulatory pathways and demonstrating safety and efficacy for new indications.
- Scalability
- The scalability of Azzam's lab's functional testing platform will be a key factor in determining its widespread adoption and impact on cancer treatment.
Related topics